These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 31748962)

  • 1. Spanish validation of Charlson index applied to prostate cancer.
    Casas Duran F; Valduvieco I; Oses G; Cortés KS; Barreto TD; Muñoz-Guglielmetti D; Ferrer F
    Clin Transl Oncol; 2020 Jul; 22(7):1187-1192. PubMed ID: 31748962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
    Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
    J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved prediction of long-term, other cause mortality in men with prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
    J Urol; 2011 Nov; 186(5):1868-73. PubMed ID: 21944092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
    Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond D'Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier.
    Gabriele D; Jereczek-Fossa BA; Krengli M; Garibaldi E; Tessa M; Moro G; Girelli G; Gabriele P;
    Radiat Oncol; 2016 Feb; 11():23. PubMed ID: 26911291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of renicapsular involvement in Stages I and II renal cell carcinoma from the morphological and prognostic point of view.
    May M; Brookman-Amissah S; Roigas J; Gilfrich CP; Pflanz S; Hoschke B; Gunia S
    Urol Oncol; 2010; 28(3):274-9. PubMed ID: 18805709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
    Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration.
    Sohlberg EM; Thomas IC; Yang J; Kapphahn K; Daskivich TJ; Skolarus TA; Shelton JB; Makarov DV; Bergman J; Bang CK; Goldstein MK; Wagner TH; Brooks JD; Desai M; Leppert JT
    Urol Oncol; 2020 Sep; 38(9):734.e1-734.e10. PubMed ID: 32674954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone.
    Huynh MA; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1158-67. PubMed ID: 27209511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
    Sanford NN; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):79-84. PubMed ID: 27824043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
    Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
    Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
    Daskivich TJ; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen Z; Terris MK; Freedland SJ
    J Urol; 2020 Sep; 204(3):511-517. PubMed ID: 32243242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
    Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
    Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
    Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
    Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy.
    Mossanen M; Nepple KG; Grubb RL; Androile GL; Kallogjeri D; Klein EA; Stephenson AJ; Kibel AS
    Eur Urol Oncol; 2018 Jun; 1(2):143-148. PubMed ID: 31100238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.
    Giacalone NJ; Wu J; Chen MH; Renshaw A; Loffredo M; Kantoff PW; D'Amico AV
    J Clin Oncol; 2016 Nov; 34(31):3781-3786. PubMed ID: 27601545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
    Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
    Ann Surg Oncol; 2014 Feb; 21(2):677-83. PubMed ID: 24145996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
    Rose BS; Chen MH; Wu J; Braccioforte MH; Moran BJ; Doseretz DE; Katin MJ; Ross RH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):778-784. PubMed ID: 27788950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.